

# Medical Developments International Limited

ABN 14 106 340 667

## Continuous Disclosure Committee Charter

**Date of Adoption: 30 August 2023**

## 1. The Continuous Disclosure Committee Charter

- 1.1 This Continuous Disclosure Committee Charter (**Charter**) is to be read in conjunction with Medical Development International Limited's (**Company** or **MVP**) Continuous Disclosure Policy (**Policy**).
- 1.2 The Continuous Disclosure Committee (**CDC**) will act as a delegated authority of the Board to:
  - (a) review and consider the materiality of potentially disclosable information it receives to determine whether that information is market sensitive information (as defined in the Policy) (Market Sensitive Information or Information) requiring disclosure under the ASX Listing Rules and *Corporations Act 2001 (Cth)* (Corporations Act);
  - (b) make recommendations to the Board as to the content of information to be disclosed; and
  - (c) approve certain disclosures on behalf of the Board as set out in the Continuous Disclosure Policy;
- 1.3 This Charter governs the CDC.

## 2. The powers and responsibilities of the CDC

- 2.1 The powers and responsibilities of the CDC are to:
  - (a) establish effective procedures to ensure Company employees disclose any Market Sensitive Information to the CDC in a timely fashion;
  - (b) convene as required in order to discharge its duties conferred by the Policy and this Charter;
  - (c) receive and record all potentially Market Sensitive Information referred to the CDC concerning the Company;
  - (d) review and determine whether potentially disclosable information it receives warrants referral to the Board including assessing whether such information should be disclosed to the ASX, pursuant to this Charter, the Policy, MVP's obligations under the ASX Listing Rules and the Corporations Act;
  - (e) provide confirmation to the Board (as required) that the Information has been reviewed by the CDC;
  - (f) liaise with the Company Secretary and/or the Board in relation to the disclosure of Information which the CDC determines should be disclosed;
  - (g) where necessary, seek external advice in relation to the disclosure of the Information;
  - (h) make recommendations to the Board on the content of information to be disclosed;

- (i) approve on behalf of the Company, certain disclosures on behalf of the Board (as set out in the Continuous Disclosure Policy);
- (j) where necessary, recommend to the CEO or Chair of the Board that a trading halt or voluntary suspension should be requested;
- (k) oversee the Company Secretary's administration of this Charter including monitoring the effectiveness of the Company's disclosure practices; and
- (l) make determinations on any other matter referred to the CDC in accordance with the terms of this Charter.

### **3. Membership**

3.1 The CDC consists of the following members;

- (a) Chair of the Company;
- (b) Chair of the Audit & Risk Committee;
- (c) Chief Executive Officer;
- (d) Chief Financial Officer;
- (e) General Counsel; and
- (f) Company Secretary.

The Company Secretary is the Chair of the Committee. See Annexure D of the Policy for further detail regarding the Company Secretary's role and responsibilities.

### **4. Decisions of the CDC**

4.1 CDC decisions:

- (a) require a quorum of two members. If practicable, one of these members must be the Chair of the Committee; and
- (b) may be held in person, teleconference or circular resolution via email, subject to quorum requirements and without all members of the CDC being present in one location.

### **5. Review**

5.1 Compliance with this Charter is intended to ensure that MVP's obligations under the Corporations Act and the ASX Listing Rules are met. This Charter will be reviewed annually by the CDC to ensure its effectiveness. This Charter may only be amended with approval by the Board.